Related Experiment Video
Updated: Apr 17, 2026
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Development and validation of a comorbidity scoring system for patients with cirrhosis
Peter Jepsen1, Hendrik Vilstrup2, Timothy L Lash3
1Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Insights
A new cirrhosis-specific comorbidity scoring system (CirCom) predicts mortality better than the Charlson Comorbidity Index. This CirCom tool uses 9 key comorbidities for improved patient survival prediction in cirrhosis care.
Area of Science:
- Hepatology and Gastroenterology
- Clinical Epidemiology
- Biostatistics
Background:
- Cirrhosis significantly increases mortality risk, with over 40% of patients having comorbidities.
- Existing comorbidity indices may not accurately reflect mortality risk in cirrhosis patients.
- A need exists for a cirrhosis-specific tool to assess comorbidity impact on survival.
Purpose of the Study:
- To develop and validate a cirrhosis-specific comorbidity scoring system (CirCom).
- To compare the predictive performance of CirCom against the generic Charlson Comorbidity Index.
- To identify key comorbidities influencing mortality in cirrhosis patients.
Main Methods:
- Utilized nationwide Danish health care registry data (1999-2010) for 12,976 cirrhosis patients.
- Employed Cox regression to identify 9 comorbidities with mortality hazard ratios ≥ 1.20 for the CirCom score.
- Validated CirCom performance using Harrell's C statistic and Net Reclassification Index (NRI) in separate cohorts.
Main Results:
- The CirCom score, based on 9 specific comorbidities, correlated significantly with patient mortality.
- CirCom demonstrated superior predictive accuracy compared to the Charlson Comorbidity Index, evidenced by higher C statistic (0.6% increase) and NRI (5.2% vs. 3.6%).
- Findings were consistent across validation cohorts of alcohol-related cirrhosis and chronic hepatitis C patients.
Conclusions:
- The developed CirCom scoring system effectively predicts mortality in cirrhosis patients using 9 key comorbidities.
- CirCom offers improved predictive performance and ease of use over the Charlson Comorbidity Index.
- CirCom is recommended for predicting survival and for use in epidemiological studies of cirrhosis.
Background & Aims:
At least 40% of patients with cirrhosis have comorbidities that increase mortality. We developed a cirrhosis-specific comorbidity scoring system (CirCom) to help determine how these comorbidities affect mortality and compared it with the generic Charlson Comorbidity Index.
Methods:
We used data from nationwide health care registries to identify Danish citizens diagnosed with cirrhosis in 1999-2008 (n = 12,976). They were followed through 2010 and characterized by 34 comorbidities. We used Cox regression to assign severity weights to comorbidities with an adjusted mortality hazard ratio (HR) ≥ 1.20. Each patient's CirCom score was based on, at most, 2 of these comorbidities. Performance was measured with Harrell's C statistic and the Net Reclassification Index (NRI) and results were compared with those obtained using the Charlson Index (based on 17 comorbidities). Findings were validated in 2 separate cohorts of patients with alcohol-related cirrhosis or chronic hepatitis C.
Results:
The CirCom score included chronic obstructive pulmonary disease, acute myocardial infarction, peripheral arterial disease, epilepsy, substance abuse, heart failure, nonmetastatic cancer, metastatic cancer, and chronic kidney disease; 24.2% of patients had 1 or more of these, and mortality correlated with the CirCom score. Patients' CirCom score correlated with their Charlson Comorbidity Index (Kendall's τ = 0.57; P < .0001). Compared with the Charlson Index, the CirCom score increased Harrell's C statistic by 0.6% (95% confidence interval: 0.3%-0.8%). The NRI for the CirCom score was 5.2% (95% confidence interval: 3.7%-6.9%), and the NRI for the Charlson Index was 3.6% (95% confidence interval: 2.3%-5.0%). Similar results were obtained from the validation cohorts.
Conclusions:
We developed a scoring system to predict mortality among patients with cirrhosis based on 9 comorbidities. This system had higher C statistic and NRI values than the Charlson Comorbidity Index, and is easier to use. It could therefore be a preferred method to predict death or survival of patients and for use in epidemiologic studies.
More Related Videos
Related Concept Videos
01:25Formulating and Validating Nursing Diagnosis II
Risk nursing diagnoses represent clinical judgments of an individual, family, or community more vulnerable to developing the health problem than others...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:27Diagnostic and Statistical Manual of Mental Disorders (DSM)